CytomX Therapeutics Inc（CTMX）股票分析CTMXCytomX Therapeutics Inc

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CytomX Therapeutics Inc is currently trading at $2.32, significantly below its analyst price targets of $11 to $14, indicating potential upside. However, the company has reported a staggering 92.4% year-over-year revenue decline in Q2, which raises concerns about its financial stability. The RSI is at 40.41, suggesting the stock is nearing oversold territory, but the negative sentiment from recent earnings misses and a high forward P/E of 14.20 indicates caution. Given these factors, it may be wise to hold rather than buy, as the stock could be volatile in the near term.

7 analysts cover CTMX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 9.00.